Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | CASR | P41180 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601580 | 1.00 | HDAC4 (0.55) | HDAC4HDAC8CASRACHEAOC3 | |
| SCHEMBL26378345 | 0.92 | SMN1; SMN2 (0.59) | HDAC4HDAC8CASRACHEAOC3 | |
| SCHEMBL487170 | 0.88 | CYP1A1 (0.53) | HDAC4HDAC8CASRACHETAAR1 | |
| SCHEMBL10290007 | 0.86 | CASR (0.53) | CASRACHEAOC3TAAR1L3MBTL1 | |
| SCHEMBL11619720 | 0.86 | CASR (0.53) | CASRACHEAOC3TAAR1L3MBTL1 | |
| SCHEMBL14020499 | 0.86 | SMN1; SMN2 (0.58) | HDAC4HDAC8CASRKDM4ETSHR | |
| SCHEMBL12545715 | 0.85 | KDM4E (0.46) | HDAC4HDAC8CASRAOC3TAAR1 | |
| SCHEMBL10446047 | 0.84 | AOC3 (0.53) | CASRACHEAOC3TAAR1L3MBTL1 | |
| SCHEMBL15271036 | 0.84 | CASR (0.51) | CASRACHEAOC3TAAR1L3MBTL1 | |
| SCHEMBL30345552 | 0.84 | PTGS1 (0.56) | HDAC4HDAC8CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368218-B | Method for preparing 4-diaryl methyl substituted phenol compound | 湖南理工学院 | 2024-01-02 | — | — | CN | claimed |
| CN-115368218-A | Method for preparing 4-diaryl methyl substituted phenol compound | 湖南理工学院 | 2022-11-22 | — | — | CN | claimed |
| US-8426115-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | claimed |
| US-20110033803-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | claimed |
| US-20100159392-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | claimed |
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | claimed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-1997011930-A1 | AROMATIC COMPOUND ACYLATION METHOD | RHODIA CHIMIE (FR) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996037452-A1 | METHOD FOR HYDROXYALKYLATING A CARBOCYCLIC AROMATIC ETHER | RHONE-POULENC CHIMIE (FR) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996035656-A1 | AROMATIC ETHER ACYLATION PROCESS | RHONE-POULENC CHIMIE (FR) | 1996-11-14 | — | — | WO | disclosed |
| EP-0698593-A1 | Process for the acylation of an aromatic compound | RHONE-POULENC CHIMIE (FR) | 1996-02-28 | — | — | EP | disclosed |
| US-4837301-A | FROM ALKALI MTEAL SULFIDES AND AROMATIC DIHALOGEN COMPOUNDS; IMPROVED CORROSION RESISTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| EP-0275007-A2 | Process for the preparation of highly molecular, optionally branched polyarylene sulfides | BAYER AG (DE) | 1988-07-20 | — | — | EP | disclosed |
| US-4473713-A | Hydrolysis of aryl-aliphatic ethers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | HDAC4 3365/4885HDAC8 2511/4885CASR 2390/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | HDAC4 1486/4885HDAC8 1169/4885CASR 589/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | HDAC4 1812/4885HDAC8 859/4885CASR 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.